Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

Presentation TCT 2025

Three-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions

Presenter: Sahil A. Parikh

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

Presentation TCT 2024

Real-World Study of IVL in Challenging BTK Lesions: Acute Results of the Disrupt BTK II Study

Presenter: Sahil Parikh

October 29, 2024

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

Presentation TCT 2023

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

Presenter: Ramon Varcoe

October 25, 2023

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

Presentation TCT 2017

Multilevel Disease: How Does BTK Disease Affect ATK Therapy?

Presenter: D. Christopher Metzger, Thomas Zeller, Tony Das

October 31, 2017

Presentation TCT 2015

Clinical Trial Debate: Do DCBs Work for the BTK Indication? Yes, Perform DCB Angioplasty of BTK Lesions Correctly and They Work!

Presenter: Gary M. Ansel, J. A. Mustapha, Francesco Liistro

October 12, 2015

News Conference News

DEB Promising in Critical Limb Ischemia, Femoropopliteal Arterial Disease

November 08, 2011

Advertisement

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Three-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-Eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions

What’s Going to Be Hot at TCT 2025

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

Real-World Study of IVL in Challenging BTK Lesions: Acute Results of the Disrupt BTK II Study

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

Multilevel Disease: How Does BTK Disease Affect ATK Therapy?

Clinical Trial Debate: Do DCBs Work for the BTK Indication? Yes, Perform DCB Angioplasty of BTK Lesions Correctly and They Work!

DEB Promising in Critical Limb Ischemia, Femoropopliteal Arterial Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content